The Ministry of Health is considering measures to decrease HIV transmission associated with injectable drug use, with a primary focus on a safe syringe program. Health Minister Dr. Atonio Lalabalavu emphasized in Parliament that it is crucial to explore all options without giving the impression that the ministry endorses drug use.
He noted the importance of contextualizing this issue within Fiji’s specific setting, stating, “The safe syringe program must not only aim to reduce transmission related to injectable drug use but also address concerns about promoting increased drug use.” He mentioned that this discussion needs to involve not just the ministry but also relevant stakeholders.
While global HIV rates are declining, Dr. Lalabalavu highlighted that Fiji’s situation is concerning, being the second fastest-growing nation in new HIV cases in the Asia-Pacific region, trailing only the Philippines. He reported that 15 percent of the 552 new HIV cases recorded in the first half of 2024 were linked to injectable drug use.
The government has been working to enhance access to HIV testing and treatment services nationwide, promoting harm reduction techniques, and combating the stigma faced by those affected by HIV. Dr. Lalabalavu announced that the Fiji National HIV Surge Strategy 2024-2027 is currently being finalized and will soon be presented to Cabinet. This strategy encompasses five key priorities aimed at reducing HIV transmissions and advancing public health treatment, care, human rights, and social justice for those affected by HIV.
For the upcoming 2024/2025 financial year, the government has allocated $200,000 for HIV/AIDS prevention and control initiatives. The ministry is also looking into additional funding sources from donors and other partners.
Furthermore, Dr. Lalabalavu mentioned efforts to enhance and decentralize point-of-care testing down to subdivision hospitals and health centers. He indicated that the recent increase in HIV cases can largely be attributed to a rise in testing rates.